Nuveen
AXSM icon

Nuveen’s Axsome Therapeutics AXSM Stock Holding History

Nuveen’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,500
Closed -$4K – 3184
2022
Q3 		$4K Buy
+86,500
New +$4.32M ﹤0.01% 3211

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's AXSM Position: Q2 2026 in Review

Nuveen reduced its Axsome Therapeutics (AXSM) stake by 43% in Q2 2026, selling an estimated $31.6M and leaving 190,080 shares worth $46.5M. The position accounts for 0.01% of the portfolio, ranked #742.

Nuveen first reported a position in AXSM in Q2 2019 and has held it in 29 quarters since. The position peaked at $63.8M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Nuveen held 190,080 shares of Axsome Therapeutics worth $46.5M as of Q2 2026.
  • Nuveen sold 145,657 Axsome Therapeutics shares in Q2 2026, an estimated $31.6M.
  • Axsome Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #742 holding.
  • Nuveen first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Axsome Therapeutics position peaked at $63.8M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.